ERBB2 and breast cancer: The median survival time of patients with luminal A, luminal B, HER2 overexpression, and triple-negative subtypes of breast cancer was 66, 60, 60, and 66 months, respectively, and there were significant differences among subtypes (P = 0.033) (Table 3).